Ignite Creation Date:
2024-05-05 @ 5:05 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00384449
Status:
COMPLETED
Last Update Posted:
2019-06-11
First Post:
2006-10-05
Brief Title:
Lucentis Ranibizumab for Eales Disease
Sponsor:
Oregon Health and Science University
Organization:
Oregon Health and Science University
Study Overview
Official Title:
The Use of a VEGF Inhibitor Lucentis in Refractory Macular Edema Due to Eales Disease
Status:
COMPLETED
Status Verified Date:
2019-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this protocol is to look at whether Lucentis ranibizumab is safe and effective when used for macular edema retinal swelling due to Eales disease The secondary objective is to see if macular edema comes back within three months after the last dose of study drug is given
Detailed Description:
This is a six-month study Eligible subjects will receive one injection of the study drug into one eye for each of three months Visual acuity blood pressure and eye pressure will be tested Subjects retinas will be examined and thickness measured by optical coherence tomography OCT Safety visits will be scheduled for the week after the injections The investigators will monitor the subjects eyes for infection and inflammation After the three-month treatment period subjects will return to the clinic monthly for four follow-up visits Procedures and tests that will be performed at the follow-up visits include visual acuity a retinal exam including OCT blood pressure and eye pressure
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None